Preventing the Next Fertility Clinic Scandal
By Jesse Reynolds,
Bioethics Forum
| 03. 13. 2009
Given the U.S. fertility industry's longstanding resistance to effective oversight, the field's two recent controversies - first octuplets, then an offer of embryo screening for cosmetic traits - shouldn't really come as a surprise. What was remarkable about the reaction they evoked from knowledgeable observers, in fact, was the chorus of agreement that it's time to leave the "Wild West" days of assisted reproduction behind.
The octuplets story turned many of us into reluctant voyeurs, fascinated by the daily dribble of details. Fortunately, at least some of the media attention soon turned away from the unsettling details about the babies' mother and focused instead on the fertility doctor involved. We soon learned that Michael Kamrava had not only transferred six embryos - two of which divided into twins - into the octuplets' mother, but had also recently put seven embryos into another woman who wanted only one child, leaving her pregnant with quadruplets.
The industry that had tolerated such irresponsible medical conduct also came under much-needed scrutiny. Many people were surprised to learn that the multibillion dollar American fertility industry...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...